GENERAL ATLANTIC, L.P. — 13F Holdings & Portfolio
CIK 1017645 · latest 13F-HR filed 2026-08-14
GENERAL ATLANTIC, L.P. manages $2.91B in 13F-reported U.S. long-equity assets across 12 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are LFTO (20.92%), DLO (20.86%), CHYM (14.98%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 3 new positions, exited 3, added to 4, and trimmed 1.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$2.91B
Long-equity book
12
Distinct positions
2026-06-30
Filed 2026-08-14
+3 / −3 / ↑4 / ↓1
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
| Name | Title / Status | Ownership | Type |
|---|
Quarter-over-quarter changes
Share-count changes vs the prior 13F.
Top Adds (vs prior quarter)
- ALKAMI$110.8M +46.1%
- CHIME$37.2M +9.3%
- NURIX THERAPEUTICS$10.0M +15.7%
- RISKIFIED$6.0M +28.6%
New Positions
- LIFTOFF MOBILE$608.1M
- SEAPORT THERAPEUTICS$132.5M
- PARABILIS MEDICINES$42.1M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | LIFTOFF MOBILE | LFTO | 53229X101 | $608.1M | 20.92% | 25,315,646 | SH |
| 2 | DLOCAL | DLO | G29018101 | $606.3M | 20.86% | 46,656,695 | SH |
| 3 | CHIME | CHYM | 16935C109 | $435.4M | 14.98% | 21,259,683 | SH |
| 4 | ALKAMI | ALKT | 01644J108 | $351.1M | 12.08% | 19,379,038 | SH |
| 5 | XP, INC | XP | G98239109 | $334.4M | 11.50% | 20,566,133 | SH |
| 6 | PHARVARIS | PHVS | N69605108 | $226.5M | 7.79% | 6,550,757 | SH |
| 7 | SEAPORT THERAPEUTICS | SPTX | 81221K108 | $132.5M | 4.56% | 6,101,582 | SH |
| 8 | NURIX THERAPEUTICS | NRIX | 67080M103 | $73.6M | 2.53% | 3,032,185 | SH |
| 9 | REVOLUTION MEDICINES | RVMD | 76155X100 | $67.0M | 2.31% | 357,791 | SH |
| 10 | PARABILIS MEDICINES | PBLS | 698955101 | $42.1M | 1.45% | 1,538,461 | SH |
| 11 | RISKIFIED | RSKD | M8216R109 | $26.8M | 0.92% | 5,324,998 | SH |
| 12 | GROVE COLLABORATIVE | GROV | 39957D201 | $3.1M | 0.11% | 2,474,859 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $2.91B | 12 | 0000950142-26-002338 |
| 2026-03-31 | 2026-05-15 | $2.15B | 12 | 0000950142-26-001406 |
| 2025-12-31 | 2026-02-17 | $2.87B | 13 | 0000950142-26-000395 |
| 2025-09-30 | 2025-11-13 | $3.33B | 16 | 0000950142-25-002960 |
33RD FLOOR
NEW YORK, NY 10055